ALTIMMUNE, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price
ALTIMMUNE, INC. (ALT) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price of $6.75 per share as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice · last filed 2026-08-12
- 2026-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price $6.75.
- 2026-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price $6.93.
- 2025-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price $6.72.
- 2025-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price $8.29.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price |
|---|---|
| 2026-06-30 | $6.75 10-Q · filed 2026-08-12 |
| 2026-03-31 | $6.93 10-Q · filed 2026-05-13 |
| 2025-12-31 | $6.72 10-K · filed 2026-03-06 |
| 2025-09-30 | $8.29 10-Q · filed 2025-11-06 |
| 2025-06-30 | $8.67 10-Q · filed 2025-08-12 |
| 2025-03-31 | $8.76 10-Q · filed 2025-05-13 |
| 2024-12-31 | $9.32 10-K · filed 2025-02-27 |
| 2024-09-30 | $9.39 10-Q · filed 2024-11-12 |
| 2024-06-30 | $9.42 10-Q · filed 2024-08-08 |
| 2024-03-31 | $9.34 10-Q · filed 2024-05-09 |
| 2023-12-31 | $9.30 10-K · filed 2024-03-27 |
| 2023-09-30 | $9.28 10-Q · filed 2023-11-07 |
| 2022-12-31 | $9.19 10-K · filed 2023-02-28 |
| 2021-12-31 | $10.81 10-K · filed 2022-03-15 |
| 2020-12-31 | $3.88 10-K · filed 2021-02-25 |
| 2019-12-31 | $3.30 10-K · filed 2020-03-27 |
| 2018-12-31 | $6.67 10-K · filed 2019-04-01 |
| 2018-09-30 | $71.32 10-Q · filed 2018-11-13 |
| 2018-06-30 | $2.59 10-Q · filed 2018-08-14 |
| 2018-03-31 | $4.02 10-Q · filed 2018-05-15 |
| 2017-12-31 | $4.62 10-K · filed 2018-04-02 |
| 2017-09-30 | $5.11 10-Q · filed 2017-11-09 |
| 2017-06-30 | $9.51 10-Q · filed 2017-08-14 |
| 2012-12-31 | $2.55 10-K · filed 2013-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |